Published in Cephalalgia on January 01, 1989
Rationale for the use of 5-HT1-like agonists in the treatment of migraine. J Neurol (1991) 1.61
Vascular 5-HT1-like receptors that mediate contraction of the dog isolated saphenous vein and carotid arterial vasoconstriction in anaesthetized dogs are not of the 5-HT1A or 5-HT1D subtype. Br J Pharmacol (1991) 1.24
Comparison of contractile responses to 5-hydroxytryptamine and sumatriptan in human isolated coronary artery: synergy with the thromboxane A2-receptor agonist, U46619. Br J Pharmacol (1993) 1.18
The effect of i.v. sumatriptan, a selective 5-HT1-receptor agonist on central haemodynamics and the coronary circulation. Br J Clin Pharmacol (1992) 1.06
Contractile 5-HT1B receptors in human cerebral arteries: pharmacological characterization and localization with immunocytochemistry. Br J Pharmacol (1999) 1.04
Further characterization of the putative 5-HT receptor which mediates blockade of neurogenic plasma extravasation in rat dura mater. Br J Pharmacol (1991) 1.02
Role of 5-HT1-like receptors in the reduction of porcine cranial arteriovenous anastomotic shunting by sumatriptan. Br J Pharmacol (1991) 0.97
Carotid vascular effects of ergotamine and dihydroergotamine in the pig: no exclusive mediation via 5-HT1-like receptors. Br J Pharmacol (1991) 0.85
Pharmacology of antimigraine drugs. J Neurol (1991) 0.79
Lack of effect of the antimigraine drugs, sumatriptan, ergotamine and dihydroergotamine on arteriovenous anastomotic shunting in the dura mater of the pig. Br J Pharmacol (1992) 0.78
Sumatriptan and cerebral perfusion in healthy volunteers. Br J Clin Pharmacol (1992) 0.77
Sumatriptan-induced saphenous venoconstriction in the anaesthetized dog through 5-HT1-like receptor activation. Br J Pharmacol (1995) 0.77
Trigeminal nerve ganglion stimulation-induced neurovascular reflexes in the anaesthetized cat: role of endothelin(B) receptors in carotid vasodilatation. Br J Pharmacol (1999) 0.76
Dilatation induced by 5-HT in the middle meningeal artery of the anaesthetised cat. Naunyn Schmiedebergs Arch Pharmacol (2004) 0.75
X. International Union of Pharmacology recommendations for nomenclature of new receptor subtypes. Pharmacol Rev (1996) 13.17
International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin). Pharmacol Rev (1994) 7.11
Proposals for the classification and nomenclature of functional receptors for 5-hydroxytryptamine. Neuropharmacology (1986) 5.83
Receptors for 5-hydroxytryptamine and noradrenaline in rabbit isolated ear artery and aorta. Br J Pharmacol (1976) 3.95
International union of pharmacology. XXIV. Current status of the nomenclature and properties of P2X receptors and their subunits. Pharmacol Rev (2001) 3.26
GR43175, a selective agonist for the 5-HT1-like receptor in dog isolated saphenous vein. Br J Pharmacol (1988) 3.03
Comparison of the actions of U-46619, a prostaglandin H2-analogue, with those of prostaglandin H2 and thromboxane A2 on some isolated smooth muscle preparations. Br J Pharmacol (1981) 2.79
Studies on the characterisation of prostanoid receptors: a proposed classification. Prostaglandins (1982) 2.73
GR32191, a highly potent and specific thromboxane A2 receptor blocking drug on platelets and vascular and airways smooth muscle in vitro. Br J Pharmacol (1989) 2.39
A comparison of 5-hydroxytryptamine receptors mediating contraction in rabbit aorta and dog saphenous vein: evidence for different receptor types obtained by use of selective agonists and antagonists. Br J Pharmacol (1985) 2.06
Classification and nomenclature of somatostatin receptors. Trends Pharmacol Sci (1995) 1.90
Evidence for two types of excitatory receptor for 5-hydroxytryptamine in dog isolated vasculature. Br J Pharmacol (1980) 1.86
Electrophysiological properties of P2X-purinoceptors in rat superior cervical, nodose and guinea-pig coeliac neurones. J Physiol (1995) 1.79
Mode of action of the anti-migraine drug sumatriptan. Trends Pharmacol Sci (1991) 1.73
Two types of excitatory receptor for 5-hydroxytryptamine in dog vasculature? [proceedings]. Br J Pharmacol (1977) 1.67
GR113808: a novel, selective antagonist with high affinity at the 5-HT4 receptor. Br J Pharmacol (1994) 1.64
AH23848: a thromboxane receptor-blocking drug that can clarify the pathophysiologic role of thromboxane A2. Circulation (1985) 1.63
Rationale for the use of 5-HT1-like agonists in the treatment of migraine. J Neurol (1991) 1.61
5-Hydroxytryptamine-induced relaxation of isolated mammalian smooth muscle. Eur J Pharmacol (1983) 1.55
5-Hydroxytryptamine contracts human coronary arteries predominantly via 5-HT2 receptor activation. Eur J Pharmacol (1989) 1.55
Ionic effects on human recombinant P2X7 receptor function. Naunyn Schmiedebergs Arch Pharmacol (1999) 1.52
Acute nociception mediated by hindpaw P2X receptor activation in the rat. Br J Pharmacol (1997) 1.46
Identification of putative 5-HT4 receptors in guinea-pig ascending colon. Eur J Pharmacol (1991) 1.46
International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification. IX. Recommendations on terms and symbols in quantitative pharmacology. Pharmacol Rev (1995) 1.45
Blockade of human P2X7 receptor function with a monoclonal antibody. Blood (1998) 1.45
Peripheral 5-hydroxytryptamine receptors and their classification. Neuropharmacology (1984) 1.43
A method for quantitating platelet aggregation and analyzing drug-receptor interactions on platelets in whole blood in vitro. J Pharmacol Methods (1981) 1.39
Further characterization of the 5-HT receptor mediating vascular relaxation and elevation of cyclic AMP in porcine isolated vena cava. Br J Pharmacol (1989) 1.39
The selective carotid arterial vasoconstrictor action of GR43175 in anaesthetized dogs. Br J Pharmacol (1989) 1.39
Receptors for 5-hydroxytryptamine: current perspectives on classification and nomenclature. Neuropharmacology (1994) 1.37
Serotonin and migraine. Ann N Y Acad Sci (1990) 1.34
Pharmacological characterization of ATP- and LPS-induced IL-1beta release in human monocytes. Br J Pharmacol (1999) 1.34
5-HT1-like receptors mediate 5-hydroxytryptamine-induced contraction of human isolated basilar artery. Br J Pharmacol (1989) 1.31
Properties of the pore-forming P2X7 purinoceptor in mouse NTW8 microglial cells. Br J Pharmacol (1997) 1.30
Naratriptan: biological profile in animal models relevant to migraine. Cephalalgia (1997) 1.30
P2X receptor-mediated excitation of nociceptive afferents in the normal and arthritic rat knee joint. Br J Pharmacol (1998) 1.29
Effects of antagonists at the human recombinant P2X7 receptor. Br J Pharmacol (1998) 1.28
Ketanserin--a novel antihypertensive drug? J Pharm Pharmacol (1982) 1.28
U-46619, a selective thromboxane A2-like agonist? [proceedings]. Br J Pharmacol (1980) 1.28
Pharmacological and anti-emetic properties of ondansetron. Eur J Cancer Clin Oncol (1989) 1.25
Characterization of 5-HT receptors mediating contraction of canine and primate basilar artery by use of GR43175, a selective 5-HT1-like receptor agonist. Br J Pharmacol (1989) 1.25
Vascular 5-HT1-like receptors that mediate contraction of the dog isolated saphenous vein and carotid arterial vasoconstriction in anaesthetized dogs are not of the 5-HT1A or 5-HT1D subtype. Br J Pharmacol (1991) 1.24
Cloning and functional characterisation of the mouse P2X7 receptor. FEBS Lett (1998) 1.21
Complexities of measuring antagonist potency at P2X(7) receptor orthologs. J Pharmacol Exp Ther (2001) 1.20
The effects of uptake1 on alpha-adrenoceptor antagonist potency in dog saphenous vein. Br J Pharmacol (1978) 1.19
5-Carboxamidotryptamine is a selective agonist at 5-hydroxytryptamine receptors mediating vasodilatation and tachycardia in anaesthetized cats. Br J Pharmacol (1986) 1.17
Adenosine nucleotides acting at the human P2Y1 receptor stimulate mitogen-activated protein kinases and induce apoptosis. J Biol Chem (2001) 1.16
Functional characterization of the P2X(4) receptor orthologues. Br J Pharmacol (2000) 1.16
Investigation into the 5-hydroxytryptamine receptor mediating smooth muscle relaxation in the rat oesophagus. Br J Pharmacol (1991) 1.15
Distribution and characterisation of [3H]alpha,beta-methylene ATP binding sites in the rat. Naunyn Schmiedebergs Arch Pharmacol (1993) 1.15
Apparent species differences in the kinetic properties of P2X(7) receptors. Br J Pharmacol (2000) 1.14
Influence of the endothelium on contractile effects of 5-hydroxytryptamine and selective 5-HT agonists in canine basilar artery. Br J Pharmacol (1989) 1.12
Presynaptic inhibitory action of 5-hydroxytryptamine in dog isolated saphenous vein. Br J Pharmacol (1979) 1.12
P2X1 receptor activation in HL60 cells. Blood (1996) 1.11
Excitatory effect of P2X receptor activation on mesenteric afferent nerves in the anaesthetised rat. J Physiol (1999) 1.11
Single-nucleotide polymorphism alleles in the insulin receptor gene are associated with typical migraine. Genomics (2001) 1.11
Preclinical studies on the anti-migraine drug, sumatriptan. Eur Neurol (1991) 1.10
A study on P2X purinoceptors mediating the electrophysiological and contractile effects of purine nucleotides in rat vas deferens. Br J Pharmacol (1995) 1.09
5-Carboxamidotryptamine: a potent agonist mediating relaxation and elevation of cyclic AMP in the isolated neonatal porcine vena cava. Life Sci (1986) 1.09
Localization of P2X purinoceptor transcripts in the rat nervous system. Mol Pharmacol (1995) 1.08
GR127935: a potent and selective 5-HT1D receptor antagonist. Behav Brain Res (1996) 1.07
Studies on the characterization of prostanoid receptors. Adv Prostaglandin Thromboxane Leukot Res (1983) 1.07
A pre-junctional action of 5-hydroxytryptamine and methysergide on noradrenergic nerves in dog isolated saphenous vein. J Pharm Pharmacol (1981) 1.06
Evidence for the existence of 5-hydroxytryptamine receptors, which are not of the 5-HT2 type, mediating contraction of rabbit isolated basilar artery. Br J Pharmacol (1986) 1.05
Somatostatin sst(2) receptor-mediated inhibition of mesenteric afferent nerves of the jejunum in the anesthetized rat. Gastroenterology (2001) 1.05
Chloride secretion in response to guanylin in colonic epithelial from normal and transgenic cystic fibrosis mice. Br J Pharmacol (1994) 1.05
Localization and functional expression of splice variants of the P2X2 receptor. Mol Pharmacol (1997) 1.04
Further evidence for two types of excitatory receptor for 5-hydroxytryptamine in dog vasculature [proceedings]. Br J Pharmacol (1977) 1.03
Antagonist effects on human P2X(7) receptor-mediated cellular accumulation of YO-PRO-1. Br J Pharmacol (2000) 1.02
Characterization of purinoceptors mediating depolarization of rat isolated vagus nerve. Br J Pharmacol (1993) 1.01
Effects of divalent cations on the potency of ATP and related agonists in the rat isolated vagus nerve: implications for P2 purinoceptor classification. Br J Pharmacol (1994) 1.01
Evidence for a presynaptic inhibitory receptor for 5-hydroxytryptamine in dog isolated saphenous vein [proceedings]. Br J Pharmacol (1978) 1.00
Activation of P2X receptors for adenosine triphosphate evokes cardiorespiratory reflexes in anaesthetized rats. J Physiol (1998) 0.99
Alignment of receptor nomenclature with the human genome: classification of 5-HT1B and 5-HT1D receptor subtypes. Trends Pharmacol Sci (1996) 0.99
An analysis of 5-hydroxytryptamine receptors mediating contraction of isolated smooth muscle. Neuropharmacology (1984) 0.99
Estimates of antagonist affinities at P2X purinoceptors in rat vas deferens. Eur J Pharmacol (1994) 0.99
The use of antagonists to characterize the receptors mediating depolarization of the rat isolated vagus nerve by alpha, beta-methylene adenosine 5'-triphosphate. Br J Pharmacol (1994) 0.98
5-HT1D binding sites in porcine brain can be sub-divided by GR43175. Br J Pharmacol (1989) 0.98
The selective P2X purinoceptor agonist, beta,gamma-methylene-L-adenosine 5'-triphosphate, discriminates between smooth muscle and neuronal P2X purinoceptors. Naunyn Schmiedebergs Arch Pharmacol (1995) 0.98
Evolution of a novel series of [(N,N-dimethylamino)propyl]- and piperazinylbenzanilides as the first selective 5-HT1D antagonists. J Med Chem (1994) 0.98
Comparative efficacies of three commercially available vaccines against West Nile Virus (WNV) in a short-duration challenge trial involving an equine WNV encephalitis model. Clin Vaccine Immunol (2007) 0.97